Oncologists Criticize CMS Proposal To Reduce Medicare Reimbursements For Anemia Medications



Monday, June 11th, 2007

A number of physicians attending the American Society of Clinical Oncology annual meeting in Chicago this week expressed concern that CMS “has gone too far” with its proposal to limit Medicare reimbursements for the treatment of cancer patients with anemia medications manufactured by Amgen and Johnson & Johnson, Dow Jones reports. [click link for full article]

Read more here…



Previous Infectious Disease Doctors Urge Congress To Cover Home Infusion Therapy For Medicare Beneficiaries

Next  Navicure Now Submits NPI Values to All Medicare, Medicaid, Blue Cross/Blue Shield and Commercial Plans